News
SNTI
0.3100
-5.86%
-0.0193
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 4d ago
Senti Biosciences Files Prospectus Covering Resale Of Up To 25,555,024 Shares Of Common Stock Offered By The Selling Securityholders
Benzinga · 4d ago
Senti Biosciences Announces Board and Committee Leadership Change
TipRanks · 4d ago
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 5d ago
Weekly Report: what happened at SNTI last week (0914-0918)?
Weekly Report · 09/21 09:22
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 09/17 21:06
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 09/16 12:06
Weekly Report: what happened at SNTI last week (0907-0911)?
Weekly Report · 09/14 09:24
Weekly Report: what happened at SNTI last week (0831-0904)?
Weekly Report · 09/07 09:22
Senti Biosciences Secures Equity Commitment Amid Merger Plans
TipRanks · 09/04 10:28
Senti Biosciences amends securities agreement, adds note tranche
TipRanks · 09/02 22:09
Weekly Report: what happened at SNTI last week (0824-0828)?
Weekly Report · 08/31 09:24
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 08/25 21:06
Weekly Report: what happened at SNTI last week (0817-0821)?
Weekly Report · 08/24 09:24
Senti Biosciences Advances Proxy for Merger and CVR
TipRanks · 08/20 21:05
Weekly Report: what happened at SNTI last week (0810-0814)?
Weekly Report · 08/17 09:24
Senti Biosciences Holdings, Inc. Reports Quarterly Results for the Period Ended June 30, 2026
Press release · 08/14 23:11
Weekly Report: what happened at SNTI last week (0803-0807)?
Weekly Report · 08/10 09:23
VOO vs VTI: Are You Owning the Wrong Vanguard ETF?
TipRanks · 08/06 13:58
Weekly Report: what happened at SNTI last week (0727-0731)?
Weekly Report · 08/03 09:23
More
Webull provides a variety of real-time SNTI stock news. You can receive the latest news about Senti Biosciences Holdings, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About SNTI
Senti Biosciences Holdings, Inc. is a wholly owned subsidiary of Senti Holdings, Inc. Senti Biosciences, Inc. is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. Its lead product candidate, SENTI-202, is a potentially first-in-class Logic Gated off-the-shelf CAR-NK cell therapy for the treatment of blood cancers currently being studied in an open-label, multi-center Phase I clinical trial for the treatment of relapsed/refractory hematological malignancies, including Acute Myeloid Leukemia.